UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000037448 |
|---|---|
| Receipt number | R000042682 |
| Scientific Title | Prospective, Multicenter, Observational Study to Evaluate Physical Activity, Bleeding Events, Quality of Daily Life, and Safety in Patients with Congenital Hemophilia A Without FVIII Inhibitors Under Emicizumab Prophylaxis |
| Date of disclosure of the study information | 2019/08/01 |
| Last modified on | 2022/07/06 10:00:37 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Prospective, Multicenter, Observational Study to Evaluate Physical Activity, Bleeding Events, Quality of Daily Life, and Safety in Patients with Congenital Hemophilia A Without FVIII Inhibitors Under Emicizumab Prophylaxis
Acronym
TSUBASA Study
An Observational Study of Emicizumab, a Bispecific Antibody recognizing coagulation factors IX and X, on Sports and physical Activities of people with haemophilia without FVIII inhibitors
Scientific Title
Prospective, Multicenter, Observational Study to Evaluate Physical Activity, Bleeding Events, Quality of Daily Life, and Safety in Patients with Congenital Hemophilia A Without FVIII Inhibitors Under Emicizumab Prophylaxis
Scientific Title:Acronym
TSUBASA Study
An Observational Study of Emicizumab, a Bispecific Antibody recognizing coagulation factors IX and X, on Sports and physical Activities of people with haemophilia without FVIII inhibitors
Region
| Japan |
Condition
Condition
Congenital hemophilia A
Classification by specialty
| Hematology and clinical oncology | Pediatrics |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
1.To document, in an exploratory manner, the relationship between exercise status and bleeds in patients on prophylactic treatment with recombinant emicizumab.
2.To evaluate, in an exploratory manner, the quality and content of daily life during prophylactic treatment with emicizumab.
3.To collect information on the safety of emicizumab in clinical settings.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
1.Endpoints Related to Exercise Status and Bleeds:Patient-reported exercise status. Patient-reported status of bleeds attributable to exercise. Data of physical activity during exercise from wearable activity tracker.
2.Endpoints Related to Quality and Nature of Daily Life:Patient Health Related Quality of Life (HRQoL) determined with SF-36 scores or J-KIDSCREEN-52 scores. Work/study status determined with WPAI+CIQ:HS.
Survey of physical activity with IPAQ. Questionnaire-based survey on daily life of patients and caregivers
Data of non-exercise physical activity from wearable activity tracker.
3.Endpoints Related to Safety:Overall evaluation of the following measures on safety during emicizumab prophylactic treatment.
-Adverse events, Presence of FVIII inhibitors
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
(1) Informed consent form signed by the patient or legally acceptable representative Assent to participate in the study with signed informed assent form from pediatric patients when possible.
(2) Diagnosis of congenital hemophilia A without FVIII inhibitors at the time of enrollment.
(3) Patients for whom emicizumab treatment is selected as the most appropriate form of care (patients scheduled to receive emicizumab treatment in physician-patient treatment selection) and who are scheduled to undergo treatment per the latest package insert.
Key exclusion criteria
(1) Inherited or acquired bleeding disorder other than congenital hemophilia A.
(2) Undergoing immune tolerance induction (ITI) at the time of enrollment.
(3) Previous use of emicizumab.
(4) Any other reason that, in the judgment of the investigator, would render the patient unsuitable for study participation.
Target sample size
160
Research contact person
Name of lead principal investigator
| 1st name | Kagehiro / Keiji / Teruhisa |
| Middle name | |
| Last name | Amano / Nogami / Fujii |
Organization
Tokyo Medical University / Nara Medical University / Hiroshima University Hospital
Division name
Department of Laboratory Medicine / Department of Pediatrics / Division of Blood Transfusion&Hemophilia Treatment Center
Zip code
1600023, 6348522, 7348551
Address
Nishishinjuku 6-7-1,Shinjuku-ku,Tokyo,Japan / Shijo-cho 840, Kashihara,Nara,Japan / Kasumi 1-2-3,Minami-ku,Hiroshima,Japan
TEL
(03-3342-6111)(0744-22-3051)(082-257-5555)
cmastudy@chugai-pharm.co.jp
Public contact
Name of contact person
| 1st name | the TSUBASA Study |
| Middle name | |
| Last name | The secretariat of |
Organization
EP-CRSU Co.,Ltd.
Division name
Clinical Research Headquarters
Zip code
1620814
Address
Acropolis TOKYO,6-29Shinogawamachi,Shinjuku-ku,Tokyo,162-0814,JAPAN
TEL
03-5804-5045
Homepage URL
prj-tsubasa@eps.co.jp
Sponsor or person
Institute
Chugai Pharmaceutical Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Chugai Pharmaceutical Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Deliberates at each ethics committee of participating site
Address
Deliberates at each ethics committee of participating site
Tel
-
cmastudy@chugai-pharm.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 08 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2019 | Year | 06 | Month | 20 | Day |
Date of IRB
| 2019 | Year | 06 | Month | 20 | Day |
Anticipated trial start date
| 2019 | Year | 11 | Month | 01 | Day |
Last follow-up date
| 2023 | Year | 10 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
(Email of lead principal investigator)
Kagehiro Amano:kamano@tokyo-med.ac.jp
Keiji Nogami:roc-noga@naramed-u.ac.jp
Teruhisa Fujii:teruchan@hiroshima-u.ac.jp
The study is a non-interventional, unblinded, non-randomized, single-arm, observational study to be conducted under clinical settings that will use healthcare information obtained as the result of providing care most appropriate to patients with no restrictions on the use and extent of tests, medications, and other medical acts performed for diagnostic or therapeutic reasons.
Management information
Registered date
| 2019 | Year | 07 | Month | 22 | Day |
Last modified on
| 2022 | Year | 07 | Month | 06 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042682
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
